1. Home
  2. IDR vs CYBN Comparison

IDR vs CYBN Comparison

Compare IDR & CYBN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Idaho Strategic Resources Inc.

IDR

Idaho Strategic Resources Inc.

HOLD

Current Price

$48.73

Market Cap

378.0M

ML Signal

HOLD

Logo Cybin Inc.

CYBN

Cybin Inc.

HOLD

Current Price

$8.28

Market Cap

416.1M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
IDR
CYBN
Founded
1996
2019
Country
United States
Canada
Employees
N/A
N/A
Industry
Precious Metals
Pharmaceuticals and Biotechnology
Sector
Basic Materials
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
378.0M
416.1M
IPO Year
N/A
N/A

Fundamental Metrics

Financial Performance
Metric
IDR
CYBN
Price
$48.73
$8.28
Analyst Decision
Strong Buy
Strong Buy
Analyst Count
1
4
Target Price
$17.50
$74.50
AVG Volume (30 Days)
745.4K
916.5K
Earning Date
11-12-2025
02-10-2026
Dividend Yield
N/A
N/A
EPS Growth
52.70
N/A
EPS
0.73
N/A
Revenue
$35,424,313.00
N/A
Revenue This Year
$55.62
N/A
Revenue Next Year
$23.93
N/A
P/E Ratio
$65.85
N/A
Revenue Growth
61.35
N/A
52 Week Low
$10.06
$4.81
52 Week High
$54.70
$10.73

Technical Indicators

Market Signals
Indicator
IDR
CYBN
Relative Strength Index (RSI) 62.33 68.97
Support Level $45.40 $7.85
Resistance Level $49.26 $9.12
Average True Range (ATR) 3.48 0.51
MACD 0.22 0.15
Stochastic Oscillator 78.66 68.59

Price Performance

Historical Comparison
IDR
CYBN

About IDR Idaho Strategic Resources Inc.

Idaho Strategic Resources Inc is a vertically integrated, operating junior mining company. It produces gold at the Golden Chest Mine. In addition to gold and gold production, the company maintains a strategic and domestic presence in the Critical Minerals sector and is focused on advancing its officially recognized Lemhi Pass, Diamond Creek, and Roberts Rare Earth Element projects in central Idaho.

About CYBN Cybin Inc.

Cybin Inc is a biopharmaceutical company involved in creating safe and effective therapeutics for patients to address a multitude of mental health issues. The Company is a clinical-stage neuropsychiatric company focused on advancing therapies, delivery mechanisms, novel compounds, and protocols as potential treatments for various psychiatric and neurological conditions. The Company is developing technologies and delivery systems aimed at improving the pharmacokinetics of its proprietary molecules while retaining the therapeutic benefit. These new molecules and delivery systems are expected to be studied through clinical trials to confirm safety and efficacy.

Share on Social Networks: